{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Nesapidil is a vasodilator, it is used as an antiarrythmic and antihypertensive therapy.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nitromiphene (NIT; CI 628) is a triarylethylene antiestrogen shown to be effective in treatment of experimental breast cancer. Nitromiphene is one of the earliest nonsteroidal selective estrogen receptor modulators (SERMs). It is an anti-estrogen capable to translocate the estrogen receptor to the nucleus and to induce the replenishment of the cytosol receptor. Nitromiphene inhibited the uptake of [3H]-estradiol in rat whole homogenates and isolated cell nuclei tissues and the pituitary, and inhibited estradiol-induced female sexual behavior. Nitromiphene has thus been shown to suppress the growth of chemically induced and ransplantedmammary tumors in rodents. Also, Nitromiphene was shown to have potent, prolonged antiuterotropic effects in immature rats. Nitromiphene has been shown to undergo conversion to demethyl Nitromiphene (CI628M), a phenolic metabolite which had greater affinity for estrogen receptors and greater biological potency in vitro than did Nitromiphene. However, the in vivo antiestrogenic effects of Nitromiphene and demethyl Nitromiphene were similar, possibly due to facile O-demethylation of the former compound after administration.
Status:
Investigational
Source:
NCT00264667: Phase 2 Interventional Completed Metabolic Syndrome X
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodelglitazar is an oral insulin sensitiser, a peroxisome proliferator-activated receptor (PPAR) pan agonist that was under development with GlaxoSmithKline for the treatment of hyperlipidaemia, type 2 diabetes mellitus and metabolic syndrome. Sodelglitazar exerts higher binding affinity for the delta subtype as compared to gamma and alpha subtypes. Sodelglitazar was being investigated in Phase II clinical trials for the treatment of T2DM and its complications, but this research has been discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Paranyline was used in dispersible formulations of anti-inflammatory agents. Information about the current use of this drug is not available.
Status:
Investigational
Source:
INN:fluciprazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
FLUCIPRAZINE is an antitussive, antiemetic, neuroleptic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinfenoac is a chalcone derivative patented by a pharmaceutical company Biorex Laboratories from the UK. The compound is claimed for the treatment of inflammatory and allergic conditions, as well as for the treatment of the ulcerous condition of the gastrointestinal tract.
Class (Stereo):
CHEMICAL (RACEMIC)
Cinepaxadil is cinnamoyl-piperazine derivative developed by Delalande SA for treatment cardiovascular system disorders. Cinepaxadil decrease dogs cardiac activity after i.v. administration.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Amiflamine is a selective and reversible inhibitor of monoamine oxidase (MAO) type A which exerts a preferential effect on serotonin (5-HT) catabolism. The (+)-enantiomer is the active stereoisomer. In a series of p-aminosubstituted phenethylamines,
the ( + )-enantiomer of the compound amiflamine (4-dimethylamino-2-a-dimethylphenethylamine) was found
to be a potent, selective, and reversible MAO type A
inhibitor. Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy. Ki values, determined at pH 7.2, were 1.3, 0.3 and 22 uM (liver) and 0.8, 0.2 and 14 uM (hypothalamus) for amiflamine, FLA 788(+) and FLA 668(+), respectively. Monoamine oxidase-B activity was only weakly inhibited by the compounds. This initial phase I study in six normal subjects showed
that the new MAO inhibitor amiflamine can be tolerated
in single oral doses up to 80 mg without significant
pharmacologic effects. Doses up to 60 mg were tolerated without any subjective or objective effects.
Status:
Investigational
Source:
NCT03504423: Phase 3 Interventional Completed Pancreatic Cancer Metastatic
(2018)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
CPI-613 is a lipoate derivative synthesized to be catalytically inert but to potentially mimic lipoate catalytic intermediates. The drug is in phase II of clinical trials for the treatment of Myelodysplastic syndromes; Pancreatic cancer; Small cell lung cancer; Solid tumors; Bile duct cancer; Acute Myeloid leukemia. The mechanism of CPI-613 action can be explained by (I) inhibition of tumor cell pyruvate dehydrogenase complex (PDC) through activation of pyruvate dehydrogenase kinases leading to inactivating phosphorylation of the E1alpha-subunit of PDC; and (II) inhibition of alpha-ketoglutarate dehydrogenase.
Status:
Investigational
Source:
USAN:NITRALAMINE HYDROCHLORIDE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Nitralamine is an antifungal agent.
